Date: 2016-09-29
Type of information: Initiation of development program
phase: 1
Announcement: initiation of development program
Company: Threshold Pharmaceuticals (USA - CA)
Product: TH-3424
Action mechanism:
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 29, 2016, Threshold Pharmaceuticals outlined its plans to focus company resources on the more clinically-advanced evofosfamide program as well as an earlier-stage anticancer candidate, TH-3424.
The company plans to advance TH-3424 through IND-enabling toxicology studies with the goal of reaching the clinic in 2017. This new, small-molecule drug candidate, discovered at Threshold, is being evaluated for the potential treatment of hepatocellular (liver) cancer (HCC), castrate resistant prostate cancer (CRPC), T-cell acute lymphoblastic leukemias (T-ALL), and other cancers expressing high levels of aldo-keto reductase family 1 member C3 (AKR1C3). Tumors overexpressing AKR1C3 can be resistant to radiation therapy and chemotherapy. TH-3424 is a prodrug that selectively releases a potent DNA cross-linking agent in the presence of AKR1C3.
